Novel molecular targets for the therapy of urothelial cancer

Bagi R.P. Jana, Yan Zhou

    Research output: Contribution to journalReview articlepeer-review

    7 Scopus citations


    First-line platinum-based chemotherapy combinations are considered standard-of-care in locally advanced and metastatic urothelial cancer. However, longterm outcomes, including disease-specific and overall survival, remain poor. In addition, a number of patients with advanced urothelial carcinoma have co-existing medical issues that preclude the use of conventional chemotherapy. Improvements in our understanding over the molecular mechanisms of urothelial cancer have led to first-generation clinical trials evaluating novel agents targeting molecular pathways that may be relevant, at least in sub-populations. Emerging information regarding outcome with agents targeting novel molecular targets in advanced urothelial cancer is discussed in this review.

    Original languageEnglish (US)
    Pages (from-to)4557-4568
    Number of pages12
    JournalAnticancer Research
    Issue number9
    StatePublished - Sep 1 2015


    • Novel molecular targets
    • Review
    • Targeted therapy
    • Transitional cell carcinoma
    • Urothelial cancer

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research


    Dive into the research topics of 'Novel molecular targets for the therapy of urothelial cancer'. Together they form a unique fingerprint.

    Cite this